Oncology in unresectable locally advanced and metastatic cancer
Salubris Biotherapeutics Inc. focuses its clinical research on advanced solid tumours, including unresectable locally advanced cancer and metastatic cancer, with activity spanning multiple tumour types.
- Advanced solid tumours
- Unresectable locally advanced cancer
- Metastatic cancer
- Breast cancer
- Non-small cell lung cancer
The sponsor’s research portfolio includes studies aimed at evaluating anti-tumour activity alongside safety and tolerability in patients with difficult-to-treat cancer populations.
Antibody-drug conjugate development
One area of interest is the clinical investigation of antibody-drug conjugates for oncology, with attention to tumour-targeted treatment strategies in advanced disease.
- 5T4-targeted therapy
- Tumour-directed delivery
- Solid tumour therapy
This research domain reflects a focus on therapies designed to engage tumour-associated targets in advanced cancer.
Immune-based cancer therapy
The sponsor is also involved in immuno-oncology, including therapies built around IL-15 biology and CTLA-4 targeting for patients with refractory malignancies.
- IL-15 pathway modulation
- CTLA-4 targeting
- Combination oncology therapy
These studies address immune-mediated approaches for tumour control in metastatic cancer.
Monotherapy and combination treatment strategies
Clinical work also spans both monotherapy and combination therapy approaches in advanced oncology, supporting evaluation across different treatment settings.
- Single-agent treatment
- Combination regimens
- Expanded treatment cohorts
Research activity extends across multiple sites in the United States and Europe, with an emphasis on patients whose disease remains unresectable.
